Back to search results

Study of a Behavioral Intervention for Breathlessness in Advanced Lung Cancer

This study is looking at a new way to help people with advanced lung cancer manage dyspnea (difficulty breathing). It's testing an intervention called "Dyspnea Intervention (BEHAVIORAL)" which involves three nurse-led sessions focused on managing breathlessness and relaxation, plus a digital app. This is compared to "Enhanced Usual Care," which provides educational materials and standard care. The study aims to see if the behavioral intervention improves how patients report their breathlessness after 8 weeks. You might be able to join if you are at least 18 years old, have advanced lung cancer or mesothelioma not being treated to cure it, and experience at least moderate breathlessness. The study plans to enroll 420 participants, but its current status is unclear.

Study design
This is an interventional study comparing two approaches to managing breathlessness. It plans to include 420 participants.
What's involved
Participants will receive three nurse-led sessions and access to a digital health app, or educational materials and usual care. Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, patient-reported dyspnea, is measured at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06791057

Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer

Not Yet Recruiting
NAAges 18+InterventionalSupportive care
Massachusetts General Hospital
~420 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:Dyspnea InterventionEnhanced Usual Care

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient-reported Dyspnea
Measured over 8 weeks

Conditions

Advanced Lung Cancer
Dyspnea

Explore related trials

Lung Non-Small Cell CarcinomaLung Small Cell CarcinomaMesothelial Neoplasm

Where it's being run

3 sites across 3 states
Florida1
Maryland1
Massachusetts1

Who to contact

Jennifer S. Temel, MD
[email protected]
617-724-4000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years
Diagnosis of advanced lung cancer (i.e., non-small cell lung cancer or small cell lung cancer) or mesothelioma, not being treated with curative intent
Self-report at least moderate dyspnea per a rating ≥4 on the validated 0-10 breathlessness item of the Edmonton Symptom Assessment Scale-Revised
Functioning independently per an Eastern Cooperative Oncology Group Performance Status ≤2
Ability to read and respond to questions in English or Spanish
Receiving primary cancer care at one of the participating institutions

Exclusion

Significant uncontrolled psychiatric disorder or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the patient's ability to participate in study procedures.

What this trial measures

  • Patient-reported Dyspnea8 weeks

    To compare patient-reported dyspnea between study groups at 8 weeks using the Modified Medical Research Council Dyspnea Scale, which is a one-item self-report scale to evaluate the degree of a patient's dyspnea (score range: 0-4), with a higher score indicating worse dyspnea.